Aetna has gradually expanded coverage for anti-obesity medications, particularly among its commercial group plans
90 A recent clinical trial assessing the histological benefits of tirzepatide for MASH reported that tirzepatide 5 mg achieved at least one-stage improvement in fibrosis for 55% of patients without worsening MASH, and 43.6% of patients experienced MASH resolution with no worsening fibrosis
They also demonstrate significant improvements in glycemic control, blood pressure, hepatic steatosis, cardiovascular outcomes, and quality of life [2,3,4,5]
M., Kaunitz, A
No direct pharmacokinetic interactions exist between creatine and semaglutide, tirzepatide, or other GLP-1 agonists based on current clinical evidence
Co-infusion of GLP-1 and GCG has been shown to reduce glucagon-induced hyperglycemia, lower blood glucose levels, suppress food intake, and enhance energy expenditure in both diabetic obese mice and healthy human volunteers [78]